The latest update is out from Benitec Biopharma ( (BNTC) ).
On March 19, 2025, Benitec Biopharma announced positive interim results from its BB-301 Phase 1b/2a study, presented at the 2025 Muscular Dystrophy Association Conference. The study showed significant improvements in swallowing function for three subjects with Oculopharyngeal Muscular Dystrophy (OPMD), achieving clinically normal swallowing profiles and reducing dysphagic symptom burdens. These results highlight the potential of BB-301 as a promising treatment for OPMD, a condition with limited therapeutic options, and may enhance Benitec’s position in the gene therapy market.
More about Benitec Biopharma
Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on gene therapy, developing novel genetic medicines using its proprietary ‘Silence and Replace’ DNA-directed RNA interference (ddRNAi) platform.
YTD Price Performance: 28.48%
Average Trading Volume: 46,873
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $364M
For a thorough assessment of BNTC stock, go to TipRanks’ Stock Analysis page.